<description>&lt;p&gt;Welcome to a RealTalk MS special series on MS clinical trials. This special series is made possible through a generous grant from Sanofi.&lt;/p&gt; &lt;p&gt;In this final episode of this series, you'll meet Jan Janisch-Hanzlik. Jan lives with MS and is a participant in one of the clinical trials evaluating the safety and efficacy of CAR-T cell therapy for MS. &lt;/p&gt; &lt;p align="center"&gt;&lt;img src= "//assets.libsyn.com/show/105901/CARTCell2080525-20251202-lkuktgcc9w.jpg" alt="Jan Janisch-Hanzlik" width="236" height="292" /&gt;&lt;/p&gt; &lt;p&gt;In CAR-T cell therapy, blood is taken from the patient or a healthy donor, much as you would donate blood. This blood is sent to a lab, where the white blood cells, or T-cells, are separated out and reprogrammed to carry a receptor designed to fight a particular condition. This receptor is known as a &lt;em&gt;chimeric antigen receptor&lt;/em&gt;, or &lt;em&gt;CAR&lt;/em&gt;.&lt;/p&gt; &lt;p&gt;Over several weeks in the lab, these fortified T-cells multiply until there are millions of them, then they're reintroduced to the patient by intravenous infusion. CAR-T cell therapy is already used to treat some blood cancers, and Jan is the first person in the world to receive this one-and-done treatment to treat MS. She's joining us to share her experience participating in the clinical trial and to give us an update on how she's doing following her treatment. &lt;/p&gt; &lt;p&gt;This special episode of RealTalk MS is made possible by a generous grant from Sanofi. Sanofi has two ongoing Phase 3 clinical trials in MS studying &lt;strong&gt;Frexalimab&lt;/strong&gt;, an investigational second-generation anti-CD40 ligand monoclonal antibody. If you are interested in learning more about these clinical trials, please visit &lt;strong&gt;&lt;a href= "https://sanofistudies.com" target="_blank" rel= "noopener"&gt;&lt;span style= "color: #e67e23;"&gt;SanofiStudies.com&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/p&gt; &lt;div align="center"&gt; &lt;hr width="25%" /&gt;&lt;/div&gt; &lt;p style="text-align: center;"&gt;&lt;span style= "color: #e67e23;"&gt;&lt;strong&gt;SHARE THIS EPISODE OF REALTALK MS&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt; &lt;p&gt;Just copy this link &amp; paste it into your text or email: &lt;a href="https://realtalkms.com/ct4" target="_blank" rel= "noopener"&gt;&lt;strong&gt;&lt;span style= "color: #e67e23;"&gt;https://realtalkms.com/ct4&lt;/span&gt;&lt;/strong&gt;&lt;/a&gt;&lt;/p&gt; &lt;p style="text-align: center;"&gt;&lt;span style= "color: #e67e23;"&gt;&lt;strong&gt;ADD YOUR VOICE TO THE CONVERSATION&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt; &lt;p&gt;I've always thought about the RealTalk MS podcast as a conversation. And this is &lt;em&gt;your&lt;/em&gt; opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the &lt;em&gt;RealTalk MS Listener Hotline&lt;/em&gt; and share your thoughts!&lt;/p&gt; &lt;p&gt;&lt;span style="color: #e67e23;"&gt;&lt;strong&gt;Email: &lt;a style= "color: #e67e23;" href="mailto:jon@realtalkms..com" target="_blank" rel= "noopener noreferrer"&gt;jon@realtalkms.com&lt;/a&gt;&lt;/strong&gt;&lt;/span&gt;&lt;br /&gt; &lt;span style="color: #e67e23;"&gt;&lt;strong&gt;Phone: (310) 526-2283&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt; &lt;p&gt;And don't forget to join us in the &lt;span style= "color: #e67e23;"&gt;&lt;strong&gt;&lt;a style="color: #e67e23;" href= "https://facebook.com/groups/realtalkms"&gt;RealTalk MS Facebook group&lt;/a&gt;&lt;/strong&gt;&lt;/span&gt;!&lt;/p&gt; &lt;div align="center"&gt; &lt;hr width="25%" /&gt;&lt;/div&gt; &lt;div align="center"&gt; &lt;p&gt;&lt;span style="color: #d35400;"&gt;&lt;a style="color: #d35400;" href= "https://realtalkms.com/privacy-policy" target="_blank" rel= "noopener noreferrer"&gt;&lt;strong&gt;&lt;span style="color: #e67e23;"&gt;Privacy Policy&lt;/span&gt;&lt;/strong&gt;&lt;/a&gt;&lt;/span&gt;&lt;/p&gt; &lt;/div&gt;</description>

RealTalk MS

Jon Strum

Special Episode: I'm the First Participant in a CAR-T Cell Therapy Clinical Trial with Jan Janisch-Hanzlik

DEC 4, 202520 MIN
RealTalk MS

Special Episode: I'm the First Participant in a CAR-T Cell Therapy Clinical Trial with Jan Janisch-Hanzlik

DEC 4, 202520 MIN

Description

Welcome to a RealTalk MS special series on MS clinical trials. This special series is made possible through a generous grant from Sanofi.

In this final episode of this series, you'll meet Jan Janisch-Hanzlik. Jan lives with MS and is a participant in one of the clinical trials evaluating the safety and efficacy of CAR-T cell therapy for MS.

In CAR-T cell therapy, blood is taken from the patient or a healthy donor, much as you would donate blood. This blood is sent to a lab, where the white blood cells, or T-cells, are separated out and reprogrammed to carry a receptor designed to fight a particular condition. This receptor is known as a chimeric antigen receptor, or CAR.

Over several weeks in the lab, these fortified T-cells multiply until there are millions of them, then they're reintroduced to the patient by intravenous infusion. CAR-T cell therapy is already used to treat some blood cancers, and Jan is the first person in the world to receive this one-and-done treatment to treat MS. She's joining us to share her experience participating in the clinical trial and to give us an update on how she's doing following her treatment.

This special episode of RealTalk MS is made possible by a generous grant from Sanofi. Sanofi has two ongoing Phase 3 clinical trials in MS studying Frexalimab, an investigational second-generation anti-CD40 ligand monoclonal antibody. If you are interested in learning more about these clinical trials, please visit SanofiStudies.com

SHARE THIS EPISODE OF REALTALK MS

Just copy this link & paste it into your text or email: https://realtalkms.com/ct4

ADD YOUR VOICE TO THE CONVERSATION

I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts!

Email: [email protected] Phone: (310) 526-2283

And don't forget to join us in the RealTalk MS Facebook group!

Privacy Policy